Suggested remit: To appraise the clinical and cost effectiveness of melphalan flufenamide with dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma
 
Status In progress
Process STA 2018
ID number 3862

Provisional Schedule

Expected publication 25 January 2023

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2021 Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma has now been rescheduled into the work programme. The appraisal is due to start early March 2022 and will be discussed at committee in early November 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans in collaboration with the company and update our stakeholders accordingly.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
12 February 2021 - 12 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.
05 December 2017 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance